373 related articles for article (PubMed ID: 25903355)
1. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
Malm M; Vesikari T; Blazevic V
Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
[TBL] [Abstract][Full Text] [Related]
3. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
4. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
Malm M; Tamminen K; Vesikari T; Blazevic V
Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
[TBL] [Abstract][Full Text] [Related]
5. Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype.
Tamminen K; Huhti L; Vesikari T; Blazevic V
Viral Immunol; 2013 Apr; 26(2):167-70. PubMed ID: 23438469
[TBL] [Abstract][Full Text] [Related]
6. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
[TBL] [Abstract][Full Text] [Related]
7. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
[TBL] [Abstract][Full Text] [Related]
8. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.
Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y
J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863
[TBL] [Abstract][Full Text] [Related]
9. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
10. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
11. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice.
Wang X; Ku Z; Dai W; Chen T; Ye X; Zhang C; Zhang Y; Liu Q; Jin X; Huang Z
Vaccine; 2015 Oct; 33(43):5779-5785. PubMed ID: 26424606
[TBL] [Abstract][Full Text] [Related]
12. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
Malm M; Tamminen K; Vesikari T; Blazevic V
Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
[TBL] [Abstract][Full Text] [Related]
13. Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant.
Tamminen K; Malm M; Vesikari T; Blazevic V
Viruses; 2019 Jan; 11(2):. PubMed ID: 30678195
[TBL] [Abstract][Full Text] [Related]
14. Serological Correlates of Protection against a GII.4 Norovirus.
Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
[TBL] [Abstract][Full Text] [Related]
15. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
[TBL] [Abstract][Full Text] [Related]
16. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
Tamminen K; Malm M; Vesikari T; Blazevic V
Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
[TBL] [Abstract][Full Text] [Related]
17. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
[TBL] [Abstract][Full Text] [Related]
18. Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.
Blazevic V; Malm M; Vesikari T
J Med Virol; 2015 Oct; 87(10):1656-61. PubMed ID: 25946711
[TBL] [Abstract][Full Text] [Related]
19. B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.
Ramani S; Neill FH; Ferreira J; Treanor JJ; Frey SE; Topham DJ; Goodwin RR; Borkowski A; Baehner F; Mendelman PM; Estes MK; Atmar RL
Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28249841
[TBL] [Abstract][Full Text] [Related]
20. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
